IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC
Author
Barrios, C. H.
Spigel, D.
de Marinis, F.
Giaccone, G.
Reinmuth, N.
Vergnenegre, A.
Morise, M.
Felip, E.
Andric, Z. G.
Geater, S.
Mocci, S.
McCleland, M.
Enquist, I.
Komatsubara, K. M.
Deng, Y.
Kuriki, H.
Wen, X.
Jassem, J.
Herbst, R. S.
Ozguroglu, M.
Metadata
Show full item recordCollections
- Bildiri [64839]